Bicycle Therapeutics plc (NASDAQ:BCYC) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB lowered its position in shares of Bicycle Therapeutics plc (NASDAQ:BCYC) by 1.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 215,900 shares of the company’s stock after selling 2,800 shares during the quarter. Handelsbanken Fonder AB owned approximately 0.31% of Bicycle Therapeutics worth $3,023,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of BCYC. China Universal Asset Management Co. Ltd. boosted its position in Bicycle Therapeutics by 69.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock worth $162,000 after acquiring an additional 2,918 shares during the last quarter. Harbor Capital Advisors Inc. boosted its position in Bicycle Therapeutics by 141.8% during the third quarter. Harbor Capital Advisors Inc. now owns 133,707 shares of the company’s stock worth $3,026,000 after acquiring an additional 78,418 shares during the last quarter. Principal Financial Group Inc. acquired a new stake in Bicycle Therapeutics during the third quarter worth approximately $10,028,000. Assetmark Inc. acquired a new stake in Bicycle Therapeutics during the third quarter worth approximately $34,000. Finally, Crossmark Global Holdings Inc. acquired a new stake in Bicycle Therapeutics during the third quarter worth approximately $257,000. Institutional investors and hedge funds own 86.15% of the company’s stock.

Wall Street Analyst Weigh In

BCYC has been the topic of a number of analyst reports. Stephens restated an “equal weight” rating and set a $15.00 target price on shares of Bicycle Therapeutics in a research report on Wednesday, January 22nd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $35.00 price target on shares of Bicycle Therapeutics in a research note on Friday, November 1st. JMP Securities cut their price target on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a research note on Wednesday, December 18th. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price target on shares of Bicycle Therapeutics in a research note on Monday, January 13th. Finally, B. Riley cut their price target on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.43.

Bicycle Therapeutics Trading Down 3.5 %

Shares of BCYC stock opened at $11.25 on Tuesday. The company’s fifty day simple moving average is $13.51 and its 200-day simple moving average is $19.60. Bicycle Therapeutics plc has a 52 week low of $11.14 and a 52 week high of $28.67. The company has a market cap of $776.77 million, a PE ratio of -3.42 and a beta of 0.93.

Insider Activity

In other news, Director Bros. Advisors Lp Baker purchased 985,397 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The shares were purchased at an average price of $13.76 per share, with a total value of $13,559,062.72. Following the purchase, the director now directly owns 9,537,643 shares of the company’s stock, valued at approximately $131,237,967.68. This represents a 11.52 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Kevin Lee sold 9,038 shares of Bicycle Therapeutics stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total transaction of $127,345.42. Following the sale, the chief executive officer now directly owns 495,026 shares in the company, valued at $6,974,916.34. This trade represents a 1.79 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 27,677 shares of company stock valued at $392,413. Company insiders own 8.50% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.